Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04878016

A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC

Extensive-stage Small-cell Lung Cancer Clinical Trial

Official title:
A Phase III, Randomized，Double-blind Placebo-controlled Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-stage Small Cell Lung Cancer

Clinical Trial Summary

This is a randomized, Phase III, multicenter, double-blinded, placebo-controlled study designed to evaluate the safety and efficacy of ZKAB001 in combination with carboplatin + etoposide compared with treatment with placebo + carboplatin + etoposide in patients who have ES-SCLC and are untreated for their extensive-stage disease.

Clinical Trial Description

This study is a randomized, double-blind, placebo-controlled multicenter III study. Eligible patients will randomly enter the trial group or control group at 1:1, that is, ZKAB001+ carboplatin + etoposide or placebo + carboplatin + etoposide, with a treatment cycle every 3 weeks. There are 4 cycles of chemotherapy. Stratification factors included gender (male / female), PS score (0/1) and brain metastasis (yes / no). The study included screening period, treatment period (subjects received study treatment until confirmed disease progression, or intolerable toxic reaction, or reached the maximum medication cycle of 2 years, or the subject voluntarily requested the end of the study treatment) and follow-up period (including safety follow-up and survival follow-up). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04878016
Study type Interventional
Source Lee's Pharmaceutical Limited
Contact
Status Completed
Phase Phase 3
Start date July 15, 2021
Completion date October 13, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04985851 - To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. N/A
Completed NCT01987232 - Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer Phase 1/Phase 2
Recruiting NCT06223711 - Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC Phase 2
Active, not recruiting NCT05002868 - Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors Phase 1
Recruiting NCT04790253 - PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) N/A
Recruiting NCT05572476 - Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer Phase 2
Recruiting NCT05874401 - Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Phase 4
Not yet recruiting NCT06008353 - A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
Recruiting NCT04947774 - Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
Completed NCT04902885 - Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan Phase 3
Recruiting NCT05280470 - Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Phase 2
Recruiting NCT05765825 - Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC Phase 2
Recruiting NCT05761977 - Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
Active, not recruiting NCT05092412 - Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC Phase 2
Not yet recruiting NCT06306560 - A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. Phase 2
Recruiting NCT04894591 - To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
Not yet recruiting NCT06211036 - Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Phase 3
Recruiting NCT04675697 - Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer Phase 2
Recruiting NCT05796089 - Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy Phase 2
Recruiting NCT05403723 - Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Phase 1